This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Reasons Growth Investors Will Love ResMed (RMD)
by Zacks Equity Research
ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bio-Techne Inks New Agreement With Waters Corporation: Stock to Gain?
by Zacks Equity Research
TECH enters a co-marketing and co-promotion agreement with Waters Corporation to expand the reach of advanced biotherapeutic characterization and development processes.
4 Large Cap MedTech Stocks to Keep Winning Streaks Alive in 2025
by Sridatri Sarkar
Investing in large-cap MedTech stocks like MCK, PEN, CAH and PEN can be profitable for investors in 2025.
BDX Stock Down Despite New Expansion to Boost Fingertip Blood Testing
by Zacks Equity Research
The blood testing process integrating BD's MiniDraw System with Babson's BetterWay technologies is likely to lower common barriers to testing and improve patient outcomes.
NEOG Stock Gains From New Addition to the Petrifilm Product Line
by Zacks Equity Research
Neogen expands the Petrifilm product line with the introduction of Petrifilm Bacillus cereus Count Plate.
SNN Stock Might Rise Following FDA Nod for AETOS Stemless
by Zacks Equity Research
Smith & Nephew received FDA 510(k) clearance for a stemless anatomic total shoulder, AETOS Stemless. This represents a significant advancement in shoulder arthroplasty.
ZBH Stock Might Rise Following FDA Nod for OsseoFit
by Zacks Equity Research
Zimmer Biomet's OsseoFit Stemless Shoulder System gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025.
Why ResMed (RMD) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
QIAGEN Stock Gains Following the Latest Launch of IPA Interpret
by Zacks Equity Research
QGEN announces the launch of IPA Interpret to extend the analysis capabilities of a human-curated knowledge base with AI technology.
Zacks.com featured highlights include InterDigital, ResMed, Greenbrier Companies, Charles River Associates and Kontoor Brands
by Zacks Equity Research
InterDigital, ResMed, Greenbrier Companies, Charles River Associates and Kontoor Brands have been highlighted in this Screen of The Week article.
RMD or PODD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
RMD vs. PODD: Which Stock Is the Better Value Option?
5 Solid Dividend Growth Stocks to Buy Now
by Sweta Killa
InterDigital, ResMed, Greenbrier Companies, Charles River Associates and Kontoor Brands seem excellent choices for your portfolio.
Omnicell Introduces OmniSphere Platform, Stock to Gain
by Zacks Equity Research
Omnicell introduces OmniSphere. Additionally, the company showcases a full portfolio of outcomes-centric solutions at the ASHP Midyear 2024.
QIAGEN Stock Might Rise Following 1000 EZ2 Connect Placements
by Zacks Equity Research
QGEN achieves milestone with more than 1,000 EZ2 Connect placements worldwide, contributing to a global installed base of over 5,500 EZ series instruments.
Scoop Up These 3 GARP Stocks to Receive Handsome Returns
by Vasundhara Sawalka
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. RMD, OUT and CTAS are some stocks that hold promise.
Here is Why Growth Investors Should Buy ResMed (RMD) Now
by Zacks Equity Research
ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cooper Companies Q4 Earnings Beat, Revenues Miss, Stock Falls
by Zacks Equity Research
COO's top line fails to meet market expectations despite recording strong growth. However, improvement in operating margin bodes well.
PDCO Stock Gains Despite Q2 Earnings Miss and Lower Margins
by Zacks Equity Research
Patterson Companies' overall topline in the second quarter of fiscal 2025 benefits from strength in its Animal Health segment.
ZBH Stock Might Rise Following FDA Nod for Knee Implant Component
by Zacks Equity Research
Zimmer Biomet's Persona SoluTion Porous Plasma Spray Femur gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025.
Zacks Industry Outlook Highlights ResMed, Haemonetics, Phibro and Agios
by Zacks Equity Research
ResMed, Haemonetics, Phibro and Agios have been highlighted in this Industry Outlook article.
Will HAE Stock Gain Following Sell-Off of Whole Blood Assets to GVS?
by Zacks Equity Research
Haemonetics inks a new agreement to sell its whole blood assets to GVS. The transaction is expected to be closed in the first quarter of 2025.
4 Medical Product Stocks to Buy From a Prospective Industry
by Indrajit Bandyopadhyay
An ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. RMD, HAE, PAHC and AGIO are well-poised to gain from the favorable factors.
Here's Why ResMed (RMD) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.